v3.26.1
Accounts Payable and Accrued Expenses (Details) - USD ($)
 1 Months Ended 6 Months Ended
Feb. 28, 2026
Jun. 30, 2026
Dec. 31, 2025
Dec. 31, 2024
Accounts Payable and Accrued Expenses [Line Items]        
Accounts payable   $ 11,856,000 $ 14,238,000  
Accrued expenses:        
Professional fees   1,471,000 1,055,000  
Salaries, bonus and related benefits   7,329,000 7,880,000  
Research and development   428,000 277,000  
Accrued royalties payable   2,065,000 1,805,000  
Accrued coupons and rebates   19,697,000 16,547,000  
Return reserve   2,930,000 2,177,000  
Other   3,549,000 3,146,000  
Total accounts payable and accrued expenses   49,325,000 $ 47,125,000  
Mustang | uBriGene (Boston) Biosciences, Inc.        
Accrued expenses:        
Other   1,300,000   $ 1,400,000
Accrued Interest       $ 100,000
Upfront payment   $ 100,000    
Interest rate on outstanding liability   5.00%    
Mustang | uBriGene (Boston) Biosciences, Inc. | Maximum        
Accrued expenses:        
Net assets   $ 20,000,000    
Mustang | uBriGene (Boston) Biosciences, Inc. | If Mustang's net assets are below $20 million        
Accrued expenses:        
Additional payment period   6 months    
Net assets   $ 20    
Cyprium        
Accrued expenses:        
Consideration received $ 205,000,000      
Cyprium | PRV APA        
Accrued expenses:        
Consideration received $ 205,000,000      
Cyprium | PRV APA | Eunice Kennedy Shriver National Institute of Child Health and Human Development        
Accrued expenses:        
Percentage of proceeds obligated to pay 20.00%      
Gross proceeds $ 41,000,000